(HealthDay)—Children suffering from rhabdomyosarcoma, a rare cancer of the muscle tissue, may have better chances for a cure if they have extended chemotherapy, a new study finds. In a phase 3 clinical trial, adding six months of low-dose maintenance chemotherapy after initial treatment extended the five-year survival rate from 74 percent to 87 percent, researchers found. Children with rhabdomyosarcoma who’ve […]

Continue reading »